Pharmacotherapy of Neuropathic Pain

(Updated February 2022)

The chart below reviews pharmacologic options for neuropathic pain. If monotherapy fails, combo therapy can be tried.1,7,13 Meds that are NOT recommended include carbamazepine (except for trigeminal neuralgia [beyond the scope of this chart]), levetiracetam, and mexiletine.1,7 There are no studies using acetaminophen or nonsteroidal antiinflammatory drugs (NSAIDs).A 30% to 50% decrease in pain on a 10-point pain scale is typical.For other interventions to consider, see footnote d.

--Information in table may differ from product labeling--

Drug/Drug Class

Target Pain



Clinical Considerations

Preferred Options

Tricyclic antidepressants (TCAs)c

Diabetic neuropathy, postherpetic neuralgia, peripheral nerve injury, radiculopathy, poststroke pain, spinal cord injury pain, neuropathic pain in MS1,2

Amitriptyline, nortriptyline, desipramine:

  • Initial: 10 to 25 mg daily.7
  • Increase by 10 mg/week.7
  • Target dose: 10 to 150 mg once daily or divided BID.1,7 (Amitriptyline effective dose 25 to 100 mg for diabetic neuropathy [per ADA].18).

In patients ≥65 years of age: do not use >75 mg of amitriptyline, imipramine, or clomipramine.1

NNT ~ 3 to 4 for 50% pain reduction.1

For diabetic neuropathy:

  • NNT ~ 2 to 3 for 50% pain reduction.32
  • Efficacy of amitriptyline unclear.18

May not be effective for HIV neuropathy.2

Gabapentin plus nortriptyline is more effective than either alone for diabetic neuropathy or postherpetic neuralgia [Evidence Level B-1].14

Usually inexpensive.

Most studies used amitriptyline, but nortriptyline and desipramine are better tolerated.1,7,32

Can combine with pregabalin or gabapentin.1,14

Consider for patients with pain-related insomnia.2

Notable side effects: heart block, sudden death at daily doses >100 mg, sedation, constipation, dry mouth, urinary retention, blurred vision, confusion, orthostasis, weight gain.1,2 

Serotonin norepinephrine reuptake inhibitors (SNRIs)c

Diabetic neuropathy, neuropathic pain in MS, chemotherapy-related peripheral neuropathy (duloxetine)1,7


  • Initial: 30 mg daily.7 (20 to 30 mg for diabetic neuropathy [per ADA].18)
  • Increase by 30 mg/week.7
  • Target dose: 60 to 120 mg once daily.1 (40 to 60 mg for diabetic neuropathy.31)


  • Initial: 37.5 mg daily.7
  • Increase by 37.5 mg each week.7
  • Target dose 150 to 225 mg once daily (extended-release).(75 to 225 mg for diabetic neuropathy [per ADA].18)


  • Initial: 50 to 100 mg/day.40
  • May increase every three days.40
  • Target dose: 200 mg/day.31

NNT ~ 6 to 7 for 50% pain reduction.1

For diabetic neuropathy:

  • NNT ~ 3 to 5 for 50% pain reduction.32
  • Most/best evidence is for duloxetine.31

Duloxetine has the most data.

  • FDA- and Health Canada-approved for diabetic neuropathy.
  • A drug of choice for diabetic neuropathy (per ADA).12

Consider for patients with comorbid depression or anxeity.31 Effective in depressed and nondepressed patients.2

Notable side effects: nausea (duloxetine >venlafaxine), anorexia, constipation, dry mouth, sweating, anxiety, hypertension (venlafaxine >duloxetine), insomnia (venlafaxine >duloxetine),2 dizziness,19 sexual dysfunction (venlafaxine >duloxetine).39

Gabapentin or pregabalin

Diabetic neuropathy, postherpetic neuralgia, peripheral nerve injury, poststroke pain (pregabalin), spinal cord injurypain (pregabalin)1,2

Gabapentin IR:

  • Initial: 100 to 300 mg daily.7
  • Increase by 100 to 300 mg/week.7
  • Target dose 1,200 to 3,600 mg/day (1,800 to 3,600 mg/day for diabetic neuropathy18), divided TID.1
  • Requires dose reduction in kidney impairment.7


  • start with 25 to 150 mg daily, divided.7
  • Increase weekly by 25 to 150 mg.7
  • Target dose 300 to 600 mg/day, divided BID.
  • Requires dose reduction in kidney impairment.7

For postherpetic neuralgia, NNT ~ 7 to 8 for 50% pain reduction.22,28

For diabetic neuropathy, NNT ~ 5 to 6 for 50% pain reduction.32

Gabapentin plus nortriptyline is more effective than either drug alone for diabetic neuropathy or postherpetic neuralgia [Evidence Level B-1].14

FDA- and Health Canada-approved for postherpetic neuralgia (gabapentin [US], pregabalin), diabetic neuropathy (pregabalin [a drug of choice, per ADA]12), and spinal cord injury (pregabalin).


  • has a more predictable dose response.
  • works faster.
  • has a narrower dosage range.
  • can be titrated faster.

Can combine with an SNRI.1

Consider for patients with anxiety or restless legs syndrome.32,33

Notable side effects: sedation, dizziness, weight gain, edema, blurred vision.1,2 

Adverse effects may be more severe in the elderly.18

Some risk (seems to be dose-dependent) of euphoria, abuse, dependence (pregabalin>gabapentin).3

Anticonvulsants (sodium channel blockers)

Diabetic neuropathy31

Titrateto the following evidence-based effective doses:31

  • Lamotrigine: 200 to 400 mg/day.
  • Oxcarbazepine: 1,400 to 1,800 mg/day.
  • Lacosamide: 400 mg/day.
  • Valproic acid: 1,000 to 1,200 mg/day (20 mg/kg).

Modestly more effective than placebo [Evidence level B-1].17,31,34.37

NNT ~4 to 8 for 50% pain reduction.17,34,37

Consider for patients with seizure disorders.31

Follow label instructions for uptitration.

Rare risk of serious skin reactions and arrhythmias (particularly lamotrigine and lacosamide).35,36

Some experts recommend against use of valproic acid for diabetic neuropathy.2

Topical Options

Lidocaine 5% patch (Rx; US only)

Localized peripheral neuropathic pain (particularly postherpetic neuralgia).1,5 No studies for diabetic neuropathy.19

One to three patches (10 x 14 cm; can cut) to affected area for 12 hours daily.5

Approval based on one single-dose and two two-week studies.5

About half of patients in the two-week clinical trials were taking an oral medication for postherpetic neuralgia.5

NNT ~ 4 for diabetic neuropathy for 50% pain reduction.32

FDA-approved for postherpetic neuralgia.5

May have some benefit.1

Good safety profile.1

Consider first-line in patients in whom side effects of systemic medications are of concern (e.g., elderly).1

Capsaicin patch (Qutenza; US; compassionate release availability [Health Canada])

Localized peripheral neuropathic pain (particularly postherpetic neuralgia, diabetic neuropathy [feet] and HIV neuropathy)1,6,7 

Applied in clinic every three months (one to four patches to affected area for 60 minutes [30 minutes for diabetic neuropathy of the feet]).6

NNT ~ 8 to 11.30

FDA-approved for postherpetic neuralgia and diabetic neuropathy of the feet.6

Concern with long-term use; may damage epidermal nerve fibers.1

Requires pre-application of topical anesthetic and blood pressure monitoring due to transient increase in pain.Local cooling or oral analgesics may be needed post-treatment.6

Capsaicin cream <1%

Localized peripheral neuropathic pain (particularly postherpetic neuralgia)7

Apply up to four times daily.15

Minimal benefit vs placebo.7

Diabetic neuropathy evidence is of low quality.19

NNT ~ 7 for 50% pain reduction.32

Counsel patients that burning sensation at application site is common, decreases over time, and can be soothed with a cool washcloth.41

Counsel patients that consistent and continued use is important for efficacy; it does not work “as needed.”41

Nonpreferred Options


Diabetic neuropathy, mixed neuropathies7

50 mg BID to QID. Max total daily dose 400 mg.8 Reduce dose in patients with kidney impairment and in the elderly.

NNT ~ 4 to 5 for 50% reduction in pain, based on low-quality data.24

Third-line due to:1,19

  • safety/tolerability concerns.
  • low strength of evidence.

Experts advise against use for diabetic neuropathy.12,31

Preferred over strong opioids.1,7 Less constipation, nausea, and abuse potential than strong opioids.7,18

Can cause confusion in elderly.7,16


Consider for acute exacerbations or concomitant non-neuropathic pain.16


Diabetic neuropathy7


  • Initial: 50 mg twice daily.
  • Increase by 50 mg once or twice daily every three days.
  • Max: 250 mg twice daily.

Requires dose reduction in moderate liver impairment.4

Not recommended in severe liver or kidney disease.4

Studies conflicting and of poor quality.1,19

Nucynta ER is FDA-approved for diabetic neuropathy.

Evidence is weaker than with pregabalin or duloxetine.12

Safety concerns (e.g., respiratory depression, misuse), especially long-term.12



Postherpetic neuralgia, poststroke pain2

Use a low dose.8

Oxycodone (based on very low-quality evidence):29

  • NNT ~ 5.7 for 30% pain reduction (diabetic neuropathy).
  • NNH ~ 4.3

There is less evidence for other opioids.

Last-line due to concerns about misuse and overdose.1

Experts advise against use for diabetic neuropathy.12,31

Avoid chronic use.16

In polyneuropathy, long-term opioid use is associated with poor functional status, dependence, and overdose.25


Neuropathic pain in MS (Sativex, dronabinol), diabetic neuropathy (nabilone; efficacy unclear19)

Dronabinol (Marinol, generics [US]) for central neuropathic pain in MS:10

  • Initial: 2.5 mg daily.
  • Increase by 2.5 mg every other day.
  • Max dose: 5 mg BID.

Nabilone (Cesamet, [generics, Canada]) for diabetic neuropathy:7

  • Initial: 0.25 to 0.5 mg at bedtime.
  • Increase by 0.5 mg weekly.
  • Max dose: 3 mg BID.
  • In US, available only as 1 mg capsules.

NNT ~ 11 for 30% pain reduction, based on moderate quality evidence.23

Smoked cannabis may be effective for HIV neuropathy and other neuropathies.11,27

Misuse and psychiatric and cognitive effects of concern.23 NNH = 10 for psychiatric disorders.23

Notable side effects: dizziness, confusion, sedation.23

Long-term data lacking.23

Sativex (delta-9-tetrahydrocannabinol) buccal spray is Health Canada-approved for neuropathic pain in MS (adjunct).9

  • Can cause positive urine test for cannabinoids.7

Selective serotonin reuptake inhibitors (SSRIs)c

Diabetic neuropathy, polyneuropathy7


Poor analgesic effect.Less effective than TCAs or SNRIs.7

Fluoxetine may not be effective.7

Consider citalopram, escitalopram, or paroxetine.7

Natural Products

Alpha-lipoic acid

Diabetic neuropathy

Doses of 600 to 1,800 mg/day have been used in studies. It can take three to five weeks before improvement is noticed.20

Although it might be beneficial, there is not enough high-quality evidence to recommend to most people.20

Alpha-lipoic acid is possibly effective for decreasing sensations of burning, pain, numbness, and prickling of the feet and legs.20

Notable side effects: nausea, vomiting, dizziness, rash, hypoglycemia, hypotension.20

Coenzyme Q10

Diabetic neuropathy

400 mg once daily for 12 weeks.38

Although it might be beneficial, there is not enough high-quality evidence to recommend to most people.38


Study duration 12 weeks.38


Diabetic neuropathy

One capsule twice daily.21

Has shown only minimal improvement in patients with mild neuropathy [Evidence Level B-1].21 

A medical food. Contains the biologically active forms of folic acid, vitamin B6, and vitamin B12.21

The rationale for the product is based on B vitamins’ role in improving microvascular function, reducing oxidative stress, and preventing formation of advanced glycation end products.21 However, routine use of B vitamins for treatment of neuropathy is not recommended unless a deficiency exists or is suspected.26

Cost: $180 per month.b

  1. If a drug is effective for more than one type of peripheral neuropathic pain, efficacy for all other types can generally be assumed.2
  2. Wholesale acquisition cost (US). US medication pricing by Elsevier, accessed June 2021.
  3. Use caution combining serotonergic agents (e.g., TCAs, SNRIs, SSRIs, tramadol).2,7
  4. Other interventions include nerve blocks, spinal cord stimulation, intrathecal meds, and surgery.For diabetic neuropathy, cognitive behavioral therapy, Tai Chi, exercise, or mindfulness can be offered.31 Transcutaneous electrical nerve stimulation is not better than placebo based on low-quality studies.19 Don’t recommend tight glucose control to improve symptoms.12

Abbreviations: ADA = American Diabetes Association; BID = twice daily; ER = extended-release; HIV = human immunodeficiency virus; IR = immediate-release; MS = multiple sclerosis; QID = four times daily; SNRI = serotonin norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; TID = three times daily.

Levels of Evidence

In accordance with our goal of providing Evidence-Based information, we are citing the LEVEL OF EVIDENCE for the clinical recommendations we publish.



Study Quality


Good-quality patient-oriented evidence.*

  1. High-quality randomized controlled trial (RCT)
  2. Systematic review (SR)/Meta-analysis of RCTs with consistent findings
  3. All-or-none study


Inconsistent or limited-quality patient-oriented evidence.*

  1. Lower-quality RCT
  2. SR/Meta-analysis with low-quality clinical trials or of studies with inconsistent findings
  3. Cohort study
  4. Case control study


Consensus; usual practice; expert opinion; disease-oriented evidence (e.g., physiologic or surrogate endpoints); case series for studies of diagnosis, treatment, prevention, or screening.

*Outcomes that matter to patients (e.g., morbidity, mortality, symptom improvement, quality of life).

[Adapted from Ebell MH, Siwek J, Weiss BD, et al. Strength of Recommendation Taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician 2004;69:548-56.]


  1. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162-73.
  2. Gilron I, Baron R, Jensen T. Neuropathic pain: principles of diagnosis and treatment. Mayo Clin Proc 2015;90:532-45.
  3. Canadian Agency for Drugs and Technologies in Health. Rapid response report: summary with critical appraisal. Abuse and misuse potential of pregabalin: a review of the clinical evidence. April 24, 2012. (Accessed June 14, 2021).
  4. Prescribing information for Nucynta ER. Collegium Pharmaceutical. Stoughton, MA 02072. March 2021.
  5. Product information for Lidoderm. Endo Pharmaceuticals. Malvern, PA 19355. November 2018.
  6. Product information for Qutenza. Averitas Pharma. Morristown, NJ 07960. March 2021.
  7. Moulin D, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement by the Canadian Pain Society. Pain Res Manag 2014;19:328-35.
  8. Bates D, Schultheis BC, Hanes MC, et al. A comprehensive algorithm for management of neuropathic pain. Pain Med 2019;20(Suppl 1):S2-12.
  9. Product monograph for Sativex. Sovereign House. Histon, Cambridge, UK. CB24 9BZ. December 2019.
  10. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double-blind placebo controlled crossover trial. BMJ 2004;329:253.
  11. Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009;34:672-80.
  12. American Diabetes Association Professional Practice Committee. 12. Retinopathy, neuropathy, and foot care: standards of medical care in diabetes-2022. Diabetes Care 2022;45(Supplement_1):S185-94.
  13. Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev2012;(7):CD008943.
  14. Gilron I, Bailey JM, Tu D, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009;374:1252-61.
  15. Clinical Pharmacology powered by Clinical Key. Tampa, FL: Elsevier; 2021. (Accessed June 15, 2021).
  16. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-e88.
  17. Zhou M, Chen N, He L, et al. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev 2017;(12):CD007963.
  18. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017;40:136-54.
  19. Dy SM, Bennett WL, Sharma R, et al. Preventing complications and treating symptoms of diabetic peripheral neuropathy. comparative effectiveness review No. 187. (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. 290-2015-00006-I.). AHRQ Publication No. 17-EHC005-EF. Rockville, MD: Agency for Healthcare Research and Quality; March 2017. (Accessed June 15, 2021).
  20. TRC Healthcare. Alpha-lipoic acid. [Natural Medicines website]. October 21, 2020. Available at:,-herbs-supplements/professional.aspx?productid=767. (Accessed July 29, 2021).
  21. Fonseca VA, Lavery LA, Thethi TK, et al. Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial. Am J Med 2013;126:141-9.
  22. Derry S, Bell RF, Straube S, et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev 2019;(1):CD007076.
  23. Mucke M, Phillips T, Radbruch L, et al. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2018;(3):CD012182.
  24. Duehmke RM, Derry S, Wiffen PJ, et al. Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev 2017;(6):CD003726.
  25. Hoffman EM, Watson JC, St Sauver J, et al. Association of long-term opioid therapy with functional status, adverse outcomes, and mortality among patients with polyneuropathy. JAMA Neurol 2017;74:773-9.
  26. American Association of Neuromuscular & Electrodiagnostic Medicine. Ten things physicians and patients should question. Updated July 12, 2018. Choosing Wisely. (Accessed June 16, 2021).
  27. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010;182:E694-701.
  28. Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017;(6):CD007938.
  29. Gaskell H, Derry S, Stannard C, Moore RA. Oxycodone for neuropathic pain in adults. Cochrane Database Syst Rev 2016;(7):CD010692.
  30. Derry S, Rice AS, Cole P, et al. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017;(1):CD007393.
  31. Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: Practice guideline update summary: report of the AAN Guideline Subcommittee. Neurology 2022;98:31-43.
  32. Khdour MR. Treatment of diabetic peripheral neuropathy: a review. J Pharm Pharmacol 2020;72:863-72.
  33. Garg A, Chilakamarri P, Koo BB. Diagnostic and treatment considerations in restless legs syndrome complicated by diabetic neuropathy. Curr Diab Rep 2021;21:66. doi: 10.1007/s11892-021-01431-2 [abstract].
  34. Shaibani A, Fares S, Selam JL, et al. Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. J Pain 2009;10:818-28.
  35. Fowler T, Bansal AS, Lozsádi D. Risks and management of antiepileptic drug induced skin reactions in the adult out-patient setting. Seizure 2019;72:61-70.
  36. Yadav R, Schrem E, Yadav V, et al. Lacosamide-related arrhythmias: a systematic analysis and review of the literature. Cureus 2021;13:e20736. doi: 10.7759/cureus.20736.
  37. Eisenberg E, Lurie Y, Braker C, et al. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 2001;5:505-9.
  38. TRC Healthcare. Coenzyme Q10. [Natural Medicines website]. September 27, 2021. Available at:,-herbs-supplements/professional.aspx?productid=938. (Accessed February 16, 2022).
  39. Clinical Resource, Antidepressant Sexual Side Effects, Pharmacist’s Letter/Prescriber’s Letter. January 2021.
  40. Allen R, Sharma U, Barlas S. Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy. J Pain Res 2014;7:339-51.
  41. Prestige Consumer Healthcare. Zostrix. Most frequently asked questions. (Accessed February 23, 2022).

Cite this document as follows: Clinical Resource, Pharmacotherapy of Neuropathic Pain. Pharmacist’s Letter/Prescriber’s Letter. July 2021. [370731]

Related Articles